Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Harold Shlevin Insider Profile
4 Followers
Harold Shlevin, Director at Galectin Therapeutics, holds 8.71K shares in Galectin Therapeutics (Ticker: GALT). Most recently, Harold Shlevin Bought $8,706 shares of Galectin Therapeutics on Jun 05, 2019 for an estimated value of 11.93K.
Harold Shlevin has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
Director
Roles that Harold Shlevin holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Jun 05, 2019 - Jun 05, 2020
Return:-27.40%
The most profitable trade made by Harold Shlevin
Harold Shlevin's Trading History
List of latest transactions for each holding click on a transaction to see Harold Shlevin's performance on stock
You May Also Like
Harold Shlevin insider profile FAQ
What is the percentage of profitable transactions made by Harold Shlevin?
The percentage of profitable transactions made by Harold Shlevin is ―.
What is the average return per transaction made by Harold Shlevin?
The average return per transaction made by Harold Shlevin is ―.
What stocks does Harold Shlevin hold?
Harold Shlevin holds: GALT stocks.
What was Harold Shlevin’s latest transaction?
Harold Shlevin latest transaction was an Informative Buy of $11.93K.
What was Harold Shlevin's most profitable transaction?
Harold Shlevin’s most profitable transaction was an Informative Buy of GALT stock on June 5, 2019. The return on the trade was -27.40%.
What is Harold Shlevin's role in Galectin Therapeutics?
Harold Shlevin's role in Galectin Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.